Solid phase peptide synthesis (standard and custom amino acids, manual and automatic, linear and cyclic)
Biomolecule library development through computational modelling, databases and structural activity relationship (SAR)
Validation via mass spectroscopy (MS, including MALDI), inductively coupled plasma (ICP-MS, ICP-OES), high performance liquid chromatography (HPLC, including LC-MS), nuclear magnetic spectroscopy (NMR), surface plasmon resonance (SPR), infra-red spectroscopy (FTIR-ATR), X-ray crystallography (XRD)
I also teach some of these topics in UBC Chemistry course CHEM461+561.
Radiochemistry
Radioisotopes: 18F, 32P, 68Ga, 111In, 161Tb, 177Lu, and more
Protein (including antibodies) and peptide radioconjugates (includes chelators)
Oligonucleotide and nucleotide radioconjugates (includes chelators)
Radiobiocatalysis (specialty in oligonucleotide biochemistry)
Labeling conditions and assay development
Quality control data and troubleshoot radiosyntheses
Method development and optimization
Inventory, shipment, and containment management
Molecular Biology
Functional (biological) assay development (e.g. MTT/MTS, ELISA, lentivirus, binding assays)
Culturing (bacterial, mammalian) and sterile workflows
Enzymology (specialty in nucleic acid-modifying enzymes)
Oligonucleotide manipulation and purification (includes HPLC)
Microscopy
Lentivirus manipulation
I also teach some of these topics in UBC Biochemistry course BIOC301.
Pre-clinical Comparative Nuclear Medicine
Positron Emission Tomography (PET) scan processing and analysis
Rodent restraint
Subcutaneous and intraperitoneal injections
Biodistribution analysis
Academic Communication
Scientific artwork (Adobe Illustrator + InDesign)
Webpage design (WordPress)
Technical writing
Peer-reviewed articles
Technology transfer documents
Scientific instruction at university level
Personal Attributes
Project leadership and collaboration across multi-disciplinary boundaries
Autonomous experimental design and execution
Robust collaboration, negotiation, and problem solving
Coaching and advising young scientists through facilitation
Fluency in English
Knowledge Areas
Chemical biology
Biochemistry
Pharmaceutical industry and business opportunity translation (specialty in radiopharmaceuticals)
Oncology (specialty in nuclear medicine)
Pharmacokinetics
As evidence of demonstrating these skills, the complete list of publications is available here.
Modification of Nucleotides for Biological Recognition
My research focuses on the chemical biology of nucleotides, exploring modifications to enhance their molecular targeting capacities and biological stability. This work is particularly relevant in advancing medical applications, as exemplified by approval of nucleic acid-based medicines such as vaccines, aptamer drugs, and nucleotide analogs.
Medical Imaging
My first leading-author publication on positron emission tomography (PET) targeting thymidine metabolism in colorectal cancer.
Development of Peptide Inhibitor Theranostics for Pre-clinical Cancer Care
In response to the persistent public health challenge posed by cancer, our research team is developing peptide inhibitor radiopharmaceuticals by integrating diagnostic and therapeutic radioisotopes (i.e. theranostics). Building on the FDA approval of Prostate Membrane Specific Antigen (PSMA)-specific radiotracers, we aim to enhance the chemical libraries of PSMA and Fibroblast Activation Protein (FAP) inhibitors (FAPI) to optimize in vivo performance. This collaborative holds promising potential for translation to human clinical trials, such as prostate and colorectal cancer.
PSMA Analogs with clinically impactful bio-distribution
Careful choice of amino acid in PSMA analogs reduces salivary gland uptake.
Structural Activity Relationship of Small Molecule Inhibitors
My work delves into the structural activity relationship of small molecule inhibitors, with a focus on α-amanitin, a potent neurotoxin isolated from the death cap mushroom Amanita phalloides. Leveraging the first total synthesis of amanitin, I aim to explore its close analogs to identify more potent toxins for targeted cancer therapy, tapping into the immense potential of natural products as potent drugs.
Novel antibody-amanitin conjugates
By studying the hydroxy-proline residue, novel antibody-drug conjugates (ADCs) with synthetic amanitin analogs were tested in vitro for the first time.